Want to see CMPX full AI Analyst Report?
Top Page
Compass Therapeutics
(NASDAQ:CMPX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▼(-66.67% Downside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by weak financial performance (pre-revenue profile with sizable losses and worsening cash burn), which elevates financing and dilution risk. Offsetting this, corporate events are a clear positive due to encouraging late-stage clinical results and a stated regulatory/commercialization path. Technicals remain mixed with the stock still below key longer-term moving averages, and valuation signals are limited due to negative earnings and no dividend.
Positive Factors
Strong Phase 2/3 efficacy for tovecimig
COMPANION-002 demonstrated statistically significant PFS and higher ORR for tovecimig plus paclitaxel versus paclitaxel alone in a 168-patient second-line biliary tract cancer study. Durable efficacy and tolerability create a substantive clinical basis for regulatory discussions and commercial planning.
Negative Factors
Pre-revenue with sizable, worsening losses
Compass remains pre-revenue with substantial, persistent losses (TTM net income -$68.2M) and negative free cash flow (-$53.3M). Operating cash outflows have worsened over time, reducing internal funding capacity and making the company reliant on external capital to sustain operations and trial/commercial timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Phase 2/3 efficacy for tovecimig
COMPANION-002 demonstrated statistically significant PFS and higher ORR for tovecimig plus paclitaxel versus paclitaxel alone in a 168-patient second-line biliary tract cancer study. Durable efficacy and tolerability create a substantive clinical basis for regulatory discussions and commercial planning.
Read all positive factors
Compass Therapeutics (CMPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$369.18M
Dividend YieldN/A
Average Volume (3M)3.09M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth-100.00%
EPS Growth-2.72%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding180,087,920
10 Day Avg. Volume2,168,338
30 Day Avg. Volume3,085,196
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.38Price Target Upside56.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.44
Revenue Forecast (FY)-$2.22M
Compass Therapeutics Business Overview & Revenue Model
Company Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a v...
How the Company Makes Money
Compass Therapeutics is a clinical-stage biotech and, as such, it generally does not generate recurring revenue from product sales unless and until a drug candidate receives regulatory approval; the primary funding source is typically external fin...
Compass Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -738.00K | -1.47M | 850.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -67.05M | -65.02M | -47.62M | -40.60M | -34.96M | -80.19M |
| Net Income | -68.17M | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
Balance Sheet | ||||||
| Total Assets | 205.17M | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M |
| Cash, Cash Equivalents and Short-Term Investments | 194.69M | 208.91M | 126.72M | 152.46M | 186.61M | 144.51M |
| Total Debt | 9.79M | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Total Liabilities | 18.70M | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M |
| Stockholders Equity | 186.47M | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M |
Cash Flow | ||||||
| Free Cash Flow | -53.29M | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M |
| Operating Cash Flow | -53.20M | -49.14M | -44.85M | -40.62M | -34.13M | -19.67M |
| Investing Cash Flow | -66.47M | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M |
| Financing Cash Flow | 133.79M | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M |
Compass Therapeutics Technical Analysis
Negative
6.00
Price Trends
2.08
Negative
3.52
Negative
4.30
Negative
Market Momentum
-0.02
Positive
39.38
Neutral
11.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPX, the sentiment is Negative. The current price of 6 is above the 20-day moving average (MA) of 2.17, above the 50-day MA of 2.08, and above the 200-day MA of 4.30, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.38 is Neutral, neither overbought nor oversold. The STOCH value of 11.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMPX.
Compass Therapeutics Risk Analysis
Compass Therapeutics disclosed 76 risk factors in its most recent earnings report. Compass Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compass Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $788.08M | -10.02 | -36.61% | ― | -75.91% | -173.33% | |
50 Neutral | $369.18M | -4.82 | -39.75% | ― | -100.00% | -2.72% | |
49 Neutral | $744.40M | -53.68 | -12.84% | ― | ― | 40.38% | |
47 Neutral | $293.47M | ― | -35.74% | ― | 146.03% | -0.87% | |
43 Neutral | $83.15M | -0.22 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
CMPX
Compass Therapeutics
2.05
-1.02
-33.22%
CTMX
CytomX Therapeutics
3.62
1.24
52.10%
GOSS
Gossamer Bio
0.17
-1.58
-90.29%
BCYC
Bicycle Therapeutics
4.21
-4.10
-49.34%
MNPR
Monopar Therapeutics Inc
111.12
64.69
139.33%
Compass Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Compass Showcases Promising Tovecimig Data, Eyes Commercialization
Positive
Jul 1, 2026
On July 1, 2026, Compass Therapeutics updated its corporate presentation to highlight new data from the COMPANION-002 Phase 2/3 trial of its lead drug candidate tovecimig in second-line biliary tract cancer, where the combination of tovecimig and ...
Business Operations and StrategyRegulatory Filings and Compliance
Compass Therapeutics Adopts Second Amended and Restated Bylaws
Positive
Jun 23, 2026
On June 22, 2026, Compass Therapeutics, Inc.’s board of directors approved a Second Amended and Restated set of bylaws, replacing the company’s July 17, 2020 bylaws in full. The updated bylaws designate the U.S. District Courts for the...
Executive/Board ChangesShareholder Meetings
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
Positive
Jun 11, 2026
On June 10, 2026, Compass Therapeutics, Inc. stockholders elected two Class III directors, Thomas J. Schuetz and Richard S. Lindahl, to serve until the 2029 annual meeting, reinforcing continuity on the company’s board. Shareholders also rat...
Business Operations and StrategyProduct-Related Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Positive
Apr 27, 2026
On April 27, 2026, Compass Therapeutics reported full secondary endpoint data from its COMPANION-002 randomized Phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel alone in 168 patients with second-line biliary tract cancer. The combina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.